FEATURED NEWS
GMP/QDP Audits & the Importance of CAPA
The conduct of audits is a key part of our Pharmaceutical Quality Systems to give us information on the activities and standards to which our suppliers and contractors operate.
EMA Reflection Paper on GMP & MAHs – considerations for QPs
In July 2021, the European Medicines Agency (EMA) published the final reflection paper entitled "Good Manufacturing Practice and the Marketing Authorisation
Merry Christmas and Happy New Year
MIAS has continued exceptional growth and development over 2021. We'd like to thank our Team, Customers and Suppliers for contributing to
Welcome to the Team
We would like to welcome Ciara Kearney, Lisa Evans, Sherry A Calimlim and Olivia McEvoy to the MIAS Pharma Team. They are
Regulations for Pharmaceuticals Post Brexit
The European Commission has published a Communication to prepare for the end of the transition period. The document is appropriately entitled "Getting ready for
Merry Christmas and Happy New Year
MIAS has continued exceptional growth and development over 2021. We'd like to thank our Team, Customers and
Welcome to the Team
We would like to welcome Ciara Kearney, Lisa Evans, Sherry A Calimlim and Olivia McEvoy to the MIAS
Good Practices for Data Management and Integrity
The pharmaceutical industry is underpinned by a large amount of documentation to show evidence of the quality,
QTA – Best Practice Design
Quality Technical Agreements (QTAs) are not just a nice-to-have; there is a regulatory requirement to have them established! QTAs are established with manufacturers, suppliers
MHRA (GxP) Inspections during COVID19
The COVID19 pandemic presents an unprecedented challenge to healthcare, the pharmaceutical industry’s supply chain and personnel movement. MHRA understands the impact of its work on
Regulations for Pharmaceuticals Post Brexit
The European Commission has published a Communication to prepare for the end of the transition period. The document is appropriately entitled "Getting ready for changes